首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Synthesis and biological evaluation of N 9- cis -cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors
【24h】

Synthesis and biological evaluation of N 9- cis -cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors

机译:N 9-顺式 - 环丁基呋喃衍生物用作细胞周期蛋白依赖性激酶(CDK)抑制剂的合成及生物学评价

获取原文
获取原文并翻译 | 示例
           

摘要

Graphical abstract Display Omitted Abstract A novel 6-aminopurine scaffold bearing an N 9- cis -cyclobutyl moiety was designed using structure-based molecular design based on two known CDK inhibitors, dinaciclib and Cmpd-27. A series of novel 6-aminopurine compounds was prepared for structure–activity relationship (SAR) studies of CDK2 and CDK5 inhibitors. Among the compounds synthesized, compound 8l displayed potent CDK2 and CDK5 inhibitory activities with low nanomolar ranges (IC 50 =2.1 and 4.8nM, respectively) and showed moderate cytotoxicity in HCT116 colon cancer and MCF7 breast cancer cell lines. Here, we report the synthesis and evaluation of novel 6-aminopurine derivatives and present molecular docking models of compound 81 with CDK2 and CDK5.
机译:图形摘要展示省略了一种基于两种已知的CDK抑制剂,Dinaciclib和CMPD-27的结构的分子设计设计了一种新的6-氨基嘌呤支架,轴承轴承N 9-CIS-环丁基部分。 为CDK2和CDK5抑制剂的结构活性关系(SAR)研究制备了一系列新的6-氨基嘌呤化合物。 在合成的化合物中,化合物8L与低纳米粗糙度(IC 50 = 2.1和4.8nm)显示有效的CDK2和CDK5抑制活性,并在HCT116结肠癌和MCF7乳腺癌细胞系中显示中等细胞毒性。 在这里,我们报告了新型6-氨基嘌呤衍生物的合成和评价,并用CDK2和CDK5将化合物81的分子对接模型存在于本分子对接模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号